K252388 is an FDA 510(k) clearance for the Vanquish Water Vapor Ablation Device. Classified as Unit, Electrosurgical, Endoscopic (with Or Without Accessories) (product code KNS), Class II - Special Controls.
Submitted by Francis Medical, Inc. (Maple Grove, US). The FDA issued a Cleared decision on November 26, 2025 after a review of 118 days - within the typical 510(k) review window.
This device falls under the Gastroenterology & Urology FDA review panel, regulated under 21 CFR 876.4300 - the FDA gastroenterology and urology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.
Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Gastroenterology & Urology review framework, consistent with the majority of Class II 510(k) submissions.
View all Francis Medical, Inc. devices
NCT05683691
Active not recruiting
Interventional
Industry-sponsored
Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer
Prospective, Multicenter, Single-Arm Study of VanquishTM Water Vapor Ablation for PrOstate CanceR
| Condition studied |
Prostate Cancer |
| Study design |
Single group |
| Eligibility |
Male only
· 50 Years+
|
| Sponsor |
Francis Medical Inc.
(industry)
|
Started 2023-05-16
→
Primary completion 2027-04-01
→
Completed 2029-04-01
Primary outcome
Primary Effectiveness Endpoint
Secondary outcome
Key Secondary Endpoint
View full study on ClinicalTrials.gov